Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients

被引：0
|
作者：
C Stephan
H Jaeger
A Carganico
G Knecht
T Lutz
C Mayr
FA Mosthaf
S Koeppe
M Mueller
E Wolf
A Tappe
E Wellmann
H Knechten
机构：
[1] Klinikum der Johann-Wolfgang-Goethe-Universität,MVZ Karlsplatz
[2] HIV Research and Clinical Care Centre,undefined
[3] Praxis Dres. S. Dupke/A. Carganico/A. Baumgarten,undefined
[4] Infektiologikum Frankfurt,undefined
[5] MVZ-Aerzteforum Seestrasse,undefined
[6] Praxis Dres. F. A. Mosthaf/M. Procaccianti/K. Zutavern-Bechtold,undefined
[7] Praxis Dres. S. Koeppe/P. Kreckel,undefined
[8] Praxis Dres. B. Frietsch/A. Ulmer/M. Mueller,undefined
[9] MUC Research,undefined
[10] Roche Pharma AG,undefined
[11] Praxenzentrum Blondelstrasse (PZB),undefined
来源：
European Journal of Medical Research | / 15卷
关键词：
HIV; protease inhibitor; saquinavir; cholesterol; triglycerides;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir
    Manosuthi, Weerawat
    Sungkanuparph, Somnuek
    Ruxrungtham, Kiat
    Prasithsirikul, Wisit
    Athichathanabadi, Chatiya
    Tantisiriwat, Woraphot
    Bowonwatanuwong, Chureeratana
    Chumpathat, Nopphanath
    Chaovavanich, Achara
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) : 127 - 129
  • [42] Efficacy and tolerability of a double boosted protease inhibitor (lopinavir plus saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
    Chetchotisakd, Ploenchan
    Anunnatsiri, S.
    Mootsikapun, P.
    Kiertiburanakul, S.
    Anekthananon, T.
    Bowonwatanuwong, C.
    Kowadisaiburana, B.
    Supparatpinyo, K.
    Ruxrungtham, K.
    HIV MEDICINE, 2007, 8 (08) : 529 - 535
  • [43] Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study
    Gori, Andrea
    Antinori, Andrea
    Vergori, Alessandra
    Cossu, Maria Vittoria
    Menzaghi, Barbara
    Sterrantino, Gaetana
    Rusconi, Stefano
    Cattelan, Anna Maria
    Castelli, Francesco
    Gianotti, Nicola
    Orofino, Giancarlo
    Ripamonti, Diego
    Savinelli, Stefano
    Manzillo, Elio
    Santantonio, Teresa Antonia
    Celesia, Benedetto Maurizio
    Cauda, Roberto
    Maserati, Renato
    Monforte, Antonella d'Arminio
    Stingone, Christof
    Bonora, Stefano
    Uglietti, Alessia
    Termini, Roberta
    Rucci, Francesco
    Mancusi, Daniela
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 84 (03) : 290 - 294
  • [44] Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients the role of gender
    Smith, Colette J.
    Sabin, Caroline A.
    Youle, Mike S.
    Lampe, Fiona C.
    Bhagani, Sanjay
    Madge, Sara
    Puradiredja, Dewi
    Johnson, Margaret A.
    Phillips, Andrew N.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (01) : 62 - 67
  • [45] Survival and Prognostic Factors of HIV-positive Patients after Antiretroviral Therapy Initiation at a Malaysian Referral Hospital
    Chet, Lee Sing
    Ab Hamid, Siti Azrin
    Bachok, Norsa'adah
    Chidambaram, Suresh Kumar
    Adnan, Wan Nor Asyikeen Wan
    SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2021, 9 (02): : 135 - +
  • [46] Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART)
    Torti, C
    Cologni, G
    Uccelli, MC
    Quiros-Roldan, E
    Imberti, L
    Airó, P
    Pirovano, S
    Patroni, A
    Tirelli, V
    Carosi, G
    VIRAL IMMUNOLOGY, 2004, 17 (02) : 279 - 286
  • [47] Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen
    Le Moing, V
    Chêne, G
    Carrieri, MP
    Alioum, A
    Brun-Vézinet, F
    Piroth, L
    Cassuto, JP
    Moatti, JP
    Raffi, F
    Leport, C
    AIDS, 2002, 16 (01) : 21 - 29
  • [48] Effect of Atazanovir, compared to other protease inhibitor-containing antiretroviral therapies, on endothelial function in HIV patients
    Flammer, A.
    Vo, T. T. N.
    Ledergerber, B.
    Hermann, F.
    Sudano, I.
    Baumgartner, I.
    Hayoz, D.
    Ruschitzka, F.
    Luscher, T. F.
    Weber, R.
    EUROPEAN HEART JOURNAL, 2007, 28 : 711 - 711
  • [49] Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study
    Echeverria, Patricia
    Bonjoch, Anna
    Puig, Jordi
    Molto, Jose
    Paredes, Roger
    Sirera, Guillem
    Ornelas, Arelly
    Perez-Alvarez, Nuria
    Clotet, Bonaventura
    Negredo, Eugenia
    PLOS ONE, 2014, 9 (02):
  • [50] Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
    Badiou, S
    De Boever, CM
    Dupuy, AM
    Baillat, V
    Cristol, JP
    Reynes, J
    ATHEROSCLEROSIS, 2003, 168 (01) : 107 - 113
12345